A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT ID: NCT07222332

Last Updated: 2026-01-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-03-31

Study Completion Date

2028-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Baricitinib

Participants will receive baricitinib orally

Group Type EXPERIMENTAL

Baricitinib

Intervention Type DRUG

Administered orally

Placebo

Participants will receive placebo orally

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baricitinib

Administered orally

Intervention Type DRUG

Placebo

Administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3009104

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention
* Have at least one diabetes-related autoantibody found at screening
* Show signs of remaining beta-cell function

* stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening, or
* random C-peptide result \>0.3 nmol/L (0.9 ng/mL) during the screening period
* Weigh at least 8 kilograms (kg) (18 pounds) at screening

Exclusion Criteria

* Have any other type of diabetes including gestational
* Have uncontrolled high blood pressure
* Have had a heart attack, heart disease, stroke, or heart failure
* Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
* Have a current or recent clinically serious medical condition or infection
Minimum Eligible Age

1 Year

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Barbara Davis Center for Childhood Diabetes

Aurora, Colorado, United States

Site Status

Children's Hospital of Philadelphia (CHOP)

Philadelphia, Pennsylvania, United States

Site Status

Driscoll Children's Hospital

Corpus Christi, Texas, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Women's and Children's Hospital

Adelaide, , Australia

Site Status

Centre for Children's Health Research

Brisbane, , Australia

Site Status

Austin Health - Repatriation Hospital

Heidelberg West, , Australia

Site Status

Ipswich Hospital

Ipswich, , Australia

Site Status

Royal Children's Hospital

Melbourne, , Australia

Site Status

Southern Adelaide Diabetes & Endocrine Services

Oaklands Park, , Australia

Site Status

The Royal Melbourne Hospital

Parkville, , Australia

Site Status

Perth Children's Hospital

Perth, , Australia

Site Status

Sydney Children's Hospital

Randwick, , Australia

Site Status

The Children's Hospital at Westmead

Westmead, , Australia

Site Status

Université Libre de Bruxelles - Hôpital Erasme

Brussels, , Belgium

Site Status

UZ Brussel

Brussels, , Belgium

Site Status

Cliniques universitaires Saint-Luc

Brussels, , Belgium

Site Status

Antwerp University Hospital

Edegem, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman

Liège, , Belgium

Site Status

CHU UCL Namur/Site Sainte Elisabeth

Namur, , Belgium

Site Status

Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne

Yvoir, , Belgium

Site Status

Hospital Universitário Maria Aparecida Pedrossian

Campo Grande, , Brazil

Site Status

Quanta Diagnóstico e Terapia

Curitiba, , Brazil

Site Status

Centro de Diabetes Curitiba

Curitiba, , Brazil

Site Status

Centro De Diabetes Metabolismo E Endocrinologia

Fortaleza, , Brazil

Site Status

Cendi - Endocrinologia e Diabetes

Goiânia, , Brazil

Site Status

Centro de Pesquisa Clínica de Marília - CPCLIM

Marília, , Brazil

Site Status

Instituto da Crianca com Diabetes

Porto Alegre, , Brazil

Site Status

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) - HCFM -T

Ribeirão Preto, , Brazil

Site Status

Universidade Federal do Rio de Janeiro

Rio de Janeiro, , Brazil

Site Status

Instituto de Pesquisa Clinica

São Paulo, , Brazil

Site Status

CPCLIN

São Paulo, , Brazil

Site Status

IBTED - Tecnologia e Educação em Diabetes

São Paulo, , Brazil

Site Status

Clínica Hepatogastro JK

São Paulo, , Brazil

Site Status

Hospital das Clinicas FMUSP

São Paulo, , Brazil

Site Status

CEDOES

Vitória, , Brazil

Site Status

Alberta Children's Hospital

Calgary, , Canada

Site Status

CIUSSS- saguenay-Lac-Saint-Jean

Chicoutimi, , Canada

Site Status

Alberta Diabetes Institute

Edmonton, , Canada

Site Status

St. Joseph's Health Care

London, , Canada

Site Status

CHUL et Centre mère-enfant Soleil

Québec, , Canada

Site Status

BC Diabetes Office

Vancouver, , Canada

Site Status

Nemocnice Jihlava

Jihlava, , Czechia

Site Status

Fakultni nemocnice Ostrava

Ostrava, , Czechia

Site Status

Milan Kvapil s.r.o., Diabetologicka ambulance

Prague, , Czechia

Site Status

New Children's Hospital

Helsinki, , Finland

Site Status

Oulun yliopistollinen sairaala

Oulu, , Finland

Site Status

Tampereen yliopistollinen sairaala

Tampere, , Finland

Site Status

Turku University Hospital

Turku, , Finland

Site Status

Hospices Civils de Lyon - Hopital Louis Pradel

Bron, , France

Site Status

Centre Hospitalier Sud Francilien

Corbeil-Essonnes, , France

Site Status

Centre Hospitalier Universitaire de Grenoble

Grenoble, , France

Site Status

Hopital Claude Huriez - CHU de Lille

Lille, , France

Site Status

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

Marseille, , France

Site Status

Pitie Salpetriere University Hospital

Paris, , France

Site Status

Hôpital Universitaire Necker Enfants Malades

Paris, , France

Site Status

Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universitaire (C -T

Paris, , France

Site Status

CHU Rangueil

Toulouse, , France

Site Status

Hannoversche Kinderheilanstalt

Hanover, , Germany

Site Status

Schwerpunktpraxis für Diabetes Hormone & Stoffwechsel

Hof, , Germany

Site Status

Universitätsklinikum Leipzig

Leipzig, , Germany

Site Status

Diabetologikum Ludwigshafen/Die Praxis am Ludwigsplatz

Ludwigshafen am Rhein, , Germany

Site Status

TUM Klinikum

München, , Germany

Site Status

RED-Institut GmbH

Oldenburg, , Germany

Site Status

Christliches Krankenhaus Quakenbrück

Quakenbrück, , Germany

Site Status

Asklepios Klinik Sankt Augustin

Sankt Augustin, , Germany

Site Status

Universitaetsklinikum Ulm

Ulm, , Germany

Site Status

Yitzhak Shamir Medical Center

Beer Yaacov, , Israel

Site Status

Soroka Medical Center

Beersheba, , Israel

Site Status

Rambam Health Care Campus

Haifa, , Israel

Site Status

Linn Medical Center

Haifa, , Israel

Site Status

Institute of Diabetes, Technology and Research - Clalit Health

Herzliya, , Israel

Site Status

Hadassah Medical Center

Jerusalem, , Israel

Site Status

Meir Medical Center

Kfar Saba, , Israel

Site Status

Schneider Children's Medical Center

Petah Tikva, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

Sheba Medical Center

Ramat Gan, , Israel

Site Status

Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Azienda Ospedaliera Universitaria Careggi

Florence, , Italy

Site Status

Azienda Ospedaliera Universitaria Meyer IRCCS

Florence, , Italy

Site Status

Azienda Ospedaliera Universitaria Di Messina G. Martino

Messina, , Italy

Site Status

Ospedale San Raffaele

Milan, , Italy

Site Status

University of Naples Federico II

Napoli, , Italy

Site Status

Azienda Ospedaliero Universitaria Maggiore della Carità

Novara, , Italy

Site Status

Azienda Ospedale - Università Padova

Padua, , Italy

Site Status

Azienda Ospedale - Università Padova

Padua, , Italy

Site Status

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento

Verona, , Italy

Site Status

Diabeter - Rotterdam

Rotterdam, , Netherlands

Site Status

Helse Fonna - Haugesund Sjukehus

Haugesund, , Norway

Site Status

Akershus Universitetssykehus

Lørenskog, , Norway

Site Status

Oslo Universitetssykehus Aker

Oslo, , Norway

Site Status

Oslo Universitetssykehus Ullevål

Oslo, , Norway

Site Status

Stavanger Universitetssykehus

Stavanger, , Norway

Site Status

St. Olavs Hospital

Trondheim, , Norway

Site Status

Uniwersyteckie Centrum Kliniczne

Gdansk, , Poland

Site Status

UMED Clinical Trials

Lodz, , Poland

Site Status

MTZ Clinical Research Powered by Pratia

Warsaw, , Poland

Site Status

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

Wroclaw, , Poland

Site Status

2Ca Braga

Braga, , Portugal

Site Status

Centro Materno Infantil do Norte

Porto, , Portugal

Site Status

ULSAM - Hospital de Santa Luzia

Viana do Castelo, , Portugal

Site Status

Unidade Local De Saude De Gaia/Espinho E.P.E.

Vila Nova de Gaia, , Portugal

Site Status

OSI Ezkerraldea-Enkarterri-Cruces - Hospital Universitario Cruces

Barakaldo, , Spain

Site Status

Hospital Clínic de Barcelona

Barcelona, , Spain

Site Status

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status

Hospital Sant Joan de Déu

Esplugues de Llobregat, , Spain

Site Status

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status

Hospital Universitario Marqués de Valdecilla

Santander, , Spain

Site Status

Hospital Universitario Virgen Del Rocio

Seville, , Spain

Site Status

Hospital Universitario Virgen Del Rocio

Seville, , Spain

Site Status

Hospital Universitari i Politecnic La Fe

Valencia, , Spain

Site Status

ProbarE i Lund AB

Lund, , Sweden

Site Status

Universitetssjukhuset Örebro

Örebro, , Sweden

Site Status

Östersunds Sjukhus

Östersund, , Sweden

Site Status

ProbarE i Stockholm AB

Stockholm, , Sweden

Site Status

CTC MTC

Uppsala, , Sweden

Site Status

Institute of Endocrinology and Metabolism named after Komissarenko

Kiev, , Ukraine

Site Status

Kyiv City Endocrinological Center

Kyiv, , Ukraine

Site Status

Zakarpattia Endoclinic

Uzhhorod, , Ukraine

Site Status

Vinnytsia Regional Clinical Endocrinology Dispensary

Vinnytsia, , Ukraine

Site Status

Aberdeen Royal Infirmary

Aberdeen, , United Kingdom

Site Status

Queen Elizabeth Hospital Birmingham

Birmingham, , United Kingdom

Site Status

Birmingham Children's Hospital

Birmingham, , United Kingdom

Site Status

Southmead Hospital

Bristol, , United Kingdom

Site Status

Addenbrooke's Hospital

Cambridge, , United Kingdom

Site Status

University Hospital of Wales

Cardiff, , United Kingdom

Site Status

Churchill Hospital

Oxford, , United Kingdom

Site Status

Southampton General Hospital

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Brazil Canada Czechia Finland France Germany Israel Italy Netherlands Norway Poland Portugal Spain Sweden Ukraine United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Role: CONTACT

317-615-4559

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

303-724-3861

Role: primary

267-426-7037

Role: primary

361-739-7250

Role: primary

434-924-5956

Role: primary

0394962160

Role: primary

0402112100

Role: primary

02 9845 3171

Role: primary

3225556305

Role: primary

0475956681

Role: primary

3227647052

Role: primary

0032 8214364

Role: primary

+3216346994

Role: primary

00 32 4 323 34 13

Role: primary

+32-81-720505

Role: primary

+32-81-720505

Role: primary

5541999736442

Role: primary

554130231252

Role: primary

5585996190895

Role: primary

5562992240229

Role: primary

55 14 21051477

Role: primary

55133372215

Role: primary

551127370277

Role: primary

551126303777

Role: primary

551197116-9844

Role: primary

5511963934548

Role: primary

55 27 99933-3330

Role: primary

519-646-6370

Role: primary

604-683-3734 x 1001

Role: primary

420567157736

Role: primary

420 597 373 522

Role: primary

420272917011

Role: primary

0445573392

Role: primary

358503539956

Role: primary

33472129525

Role: primary

33161693086

Role: primary

33 491388384

Role: primary

01 44 49 48 01

Role: primary

33140032000

Role: primary

33 5 61 32 32 18

Role: primary

4951181153331

Role: primary

0049928114037037

Role: primary

+49-341-9713116

Role: primary

0049621 62900552

Role: primary

0049 89 3187 2896

Role: primary

0049436150630128

Role: primary

05431152831

Role: primary

00492241249201

Role: primary

004973150057401

Role: primary

97289542166

Role: primary

97286244150

Role: primary

97247774411

Role: primary

97248568685

Role: primary

972-9-9613210

Role: primary

97226776927

Role: primary

972-97472559

Role: primary

97239253282

Role: primary

+97239377183

Role: primary

+972035302021

Role: primary

97236974863

Role: primary

+390902213023

Role: primary

0226432818

Role: primary

3903213733350

Role: primary

+390498212180

Role: primary

3357940960

Role: primary

0458127662

Role: primary

+31-88-280-7277

Role: primary

+47-92051592

Role: primary

+4797522277

Role: primary

48 607145644

Role: primary

+351914125573

Role: primary

961790293

Role: primary

946006000

Role: primary

+34932279846

Role: primary

+34935565661

Role: primary

+34621360800

Role: primary

34639659866

Role: primary

955012000

Role: primary

+34 955013767

Role: primary

696685777

Role: primary

46732300450

Role: primary

0732300450

Role: primary

+38 050 5958603

Role: primary

+380432531735

Role: primary

0117 4148125

Role: primary

01865857226

Role: primary

02381208518

Related Links

Access external resources that provide additional context or updates about the study.

https://trials.lilly.com/en-US/trial/662877

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-522170-36-00

Identifier Type: CTIS

Identifier Source: secondary_id

I4V-MC-JAJK

Identifier Type: OTHER

Identifier Source: secondary_id

27405

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.